# US 2026/0060969 A1 · Methods for the treatment of lymphoproliferative disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060969 A1
- Document ID: US20260060969A1
- Status: Published application
- Kind: A1
- Application number: 19/101,058
- Filed: 2023-08-03
- Published: 2026-03-05
- Earliest claimed: 2022-08-04
- Assignees: Institut National de la Sante et de la Recherche Medicale; Assistance Publique-HôPitaux De Paris (Aphp); Centre National De La Recherche Scientifique; Université Paris Cité
- Applicants: Institut National De La Santé Et De La Recherche MéDicale; Assistance Publique-HôPitaux De Paris (Aphp); Centre National De La Recherche Scientifique; Université Paris Cité
- Inventors: Guillaume CANAUD
- Web page: https://patentgrep.com/patent/US20260060969A1

## CPC

- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/52: Purines, e.g. adenine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Inventors have first investigated the impact of PIK3CA inhibition in NZBWF1/J mice a model of lymphoproliferative disorders. They randomly assigned 30 females aged of 24 weeks to receive either vehicle (n=15) or alpelisib (n=15) during 4 weeks. At the time of sacrifice, alpelisib treated mice demonstrated significantly reduced spleen size. Flow cytometry analysis revealed that B cells were significantly reduced in alpelisib treated mice and CD8 cells count corrected. They then decided to explore the relevance of alpelisib in MRL/MpJ-Faslpr/J mice (referred here as MRL-lpr), another mouse model of lymphoproliferative disorder. These mice with homozygous Fas mutation usually develop severe lymphadenoproliferation. At the time of sacrifice. MRL-lpr mice treated with alpelisib demonstrated a reduction on their spleen and lymph node sizes. Flow cytometry analysis showed correction of B cells. T cells and other immune cells in peripheral blood mononuclear cells (PBMC), lymph nodes and spleen. The invention relates to a method for treating lymphoproliferative disorder in a subject in need thereof comprising a step of administering the subject with a therapeutically effective amount of a PIK3CA inhibitor.

## Claims

### Claim 1

A method for treating a lymphoproliferative disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a PIK3CA inhibitor.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method consists essentially of administrating to the subject a therapeutically effective amount of PIK3CA inhibitor.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the lymphoproliferative disorder is a B-cell lymphoproliferative disorder.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the B-lymphoproliferative disorder is selected from the group consisting of: Hodgkin's lymphoma, Diffuse large B-cell lymphoma, acute lymphocytic leukemia, lymphoid blastic phase Chrome Myeloid Leukemia, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Extranodal marginal zone B-cell lymphomas, Mucosa-associated lymphoid tissue lymphomas, Follicular lymphoma, Mantle cell lymphoma, Nodal marginal zone B-cell lymphoma, Burkitt lymphoma, Hairy cell leukemia, Primary central nervous system lymphoma, Splenic marginal zone B-cell lymphoma, Waldenstrom's macroglobulinemia/Lymphoplasmacytic lymphoma, Multiple myeloma, Plasma cells dyscrasias, Plasma cell neoplasms, Primary mediastinal B-cell lymphoma, Hodgkin Disease and Castelman's Disease.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the lymphoproliferative disorder is a T-cell lymphoproliferative disorder.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the T-lymphoproliferative disorder is selected from the group consisting of: leukemia/lymphoma, Extranodal natural killer/T-cell lymphoma, Cutaneous T-cell lymphoma, Enteropathy-type T-cell lymphoma, Angioimmunoblastic T-cell lymphoma, Anaplastic large T/null-cell lymphoma, Subcutaneous panniculitis-like T-cell lymphoma, T-cell acute lymphocytic leukemia, T-cell large granular lymphocyte leukemia, Lymphoid blastic phase Chrome Myeloid Leukemia, post-transplantation lymphoproliferative syndromes, human T-cell leukemia virus type 1-positive (HTLV-G) adult T-cell leukemia/lymphoma (ATL), T-cell prolymphocytic leukemia (T-PLL), and unspecified T-cell lymphoma

### Claim 7 (depends on 1)

The method according to claim 1, wherein the PIK3CA inhibitor is selected from the group consisting of: BYL719, A66, GDC-0077, CYH33, TAK-117/MLN1117/INK1117 or a pharmaceutically acceptable salts thereof.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the PIK3CA inhibitor is BYL719 or a derivative thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the PIK3CA inhibitor is administered with a classical treatment.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the classical treatment is selected from the group consisting of: an intravenous immunoglobulin (IVIG), an immunosuppressor, a corticosteroid, a glucocorticoid, a mitogen-activated protein kinase (MAPK) inhibitor, a p21-activated kinase (PAK) inhibitor, an mTOR inhibitor, a tyrosine kinase inhibitor (TKI), a poly (ADP-ribose) polymerase (PARP) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, an inosine monophosphate dehydrogenase (IMPDH) inhibitor, a rituximab monoclonal antibody against T and/or B cells, chemotherapy, total body radiation and localized radiation.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

A method of screening an inhibitor of PIK3CA comprising i) providing a test compound and ii) determining the ability of said test compound to inhibit and/or reduce the activity and/or expression of PIK3CA.

### Claim 16 (depends on 9)

The method of claim 9, wherein the PIK3CA inhibitor and the classical treatment are administered simultaneously in a combined preparation, or separately, or sequentially.
